Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors

NCT02978625 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02978625
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02978625 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Talimogene Laherparepvec Followed by Talimogene Laherparepvec + Nivolumab in Refractory T Cell and NK Cell Lymphomas, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, and Other Rare Skin Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 27, 2017
Completion date
September 1, 2027
Enrollment
68 (estimated)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

anaplastic large cell lymphoma, alk-negative, anaplastic large cell lymphoma, alk-positive, apocrine carcinoma, carcinoma arising from cylindroma, carcinoma arising from spiradenoma, digital papillary adenocarcinoma, endocrine mucin-producing sweat gland carcinoma, extramammary paget disease, extraocular sebaceous carcinoma, hidradenocarcinoma, malignant sweat gland neoplasm, merkel cell carcinoma, microcystic adnexal carcinoma, nk-cell lymphoma, unclassifiable, papillary adenocarcinoma, porocarcinoma, primary cutaneous mucinous carcinoma, recurrent mature t-cell and nk-cell non-hodgkin lymphoma, recurrent t-cell non-hodgkin lymphoma, refractory anaplastic large cell lymphoma, refractory mature t-cell and nk-cell non-hodgkin lymphoma, refractory merkel cell carcinoma, refractory mycosis fungoides, refractory primary cutaneous t-cell non-hodgkin lymphoma, refractory skin squamous cell carcinoma, refractory t-cell non-hodgkin lymphoma, sezary syndrome, signet ring cell adenocarcinoma, skin adenoid cystic carcinoma, skin adnexal carcinoma, skin basal cell carcinoma, skin basosquamous cell carcinoma, skin keratoacanthoma, skin squamous cell carcinoma, squamoid eccrine ductal carcinoma, squamous cell carcinoma of unknown primary, sweat gland carcinoma, trichilemmal carcinoma, vulvar squamous cell carcinoma